Levodopa-induced dyskinesias in parkinson disease are independent of the extent of striatal dopaminergic denervation: A pharmacological and SPECT study

Clinical Neuropharmacology

Volumn 32, Issue 6, 2009, Pages 326-329

  Linazasoro, Gurutz ^a   Van Blercom, Nadege ^a   Bergaretxe, Alberto ^b   Fernández Manchola, Iñaki ^c   Laborda, Enrique ^d   Ruiz Ortega, José Angel ^e  

^a Centro Investigación Parkinson   (Spain)

^b Hospital Bidasoa   (Spain)

^c HOSPITAL DONOSTIA   (Spain)

^d Department of Nuclear Medicine   (United States)

^e UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

DaTSCAN; Levodopa induced dyskinesias; Parkinson disease; Sex

Indexed keywords

DOPAMINE; LEVODOPA; N OMEGA FLUOROPROPYL 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; DENERVATION; DISEASE DURATION; DISEASE SEVERITY; DYSKINESIA; FEMALE; HUMAN; MALE; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEX RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

AGED; BODY WEIGHT; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE; PARKINSON DISEASE, SECONDARY; SEX FACTORS; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 74249120624     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181b52792     Document Type: Article

References (22)

1. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39:561-573.
2. de la Fuente-Fernández R. Presynaptic mechanisms of motor complications in Parkinson's disease. Arch Neurol 2007;64:141-143.
3. Linazasoro G. Pathophysiology of motor complications in Parkinson's disease: postsynaptic mechanisms are crucial. Arch Neurol 2007;64:137-140.
4. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
5. Fahn S, Elton RI, Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, et al, eds. Recent Developments in Parkinson's Disease. Vol.2. Florham Park, NJ: Macmillan Healthcare Information; 1987;153-163.
6. Langston JW,Widner H, Goetz CG, et al. Core Assessment Program for Intracerebral Transplantation (CAPIT). Mov Disord 1992;7:2-13.
7. Linazasoro G, Obeso JA, Gómez JC, et al. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET. Clin Neuropharmacol 1999;22:277-281.
8. Booij J, Hemelaar TG, Speelman JD, et al. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT. J Nucl Med 1999;40:753-761.
9. Benamer HT, Patterson J, Wyper DJ, et al. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000;154:692-698.
10. Maries E, Kordower JH, Chu Y, et al. Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol Dis 2006;21:165-180.
11. Maratos EC, Jackson MJ, Pearce RK, et al. Both short-and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus). Exp Neurol 2003;179:90-102.
12. Blanchet PJ, Allard P, Grégoire L, et al. Risk factors for peak-dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci 1996;23:189-193.
13. Linazasoro G. New ideas on the pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: age, genes and neural plasticity. Trends Pharmacol Sci 2005;26:391-397.
14. Schrag A, Ben-Shlomo Y, Brown R, et al. Young-onset Parkinson's disease revisited: clinical features, natural history, and mortality. Mov Disord 1998;13:885-894.
15. Sharma JC, Macnamara L, Hasoon M, et al. Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade). Parkinsonism Relat Disord 2006;12:499-505.
16. Zappia M, Annesi G, Nicoletti G, et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease. An exploratory study. Arch Neurol 2005;62:601-605.
17. Canuti-Castelvetri I, Keller-McGandy C, Bouzou B, et al. Effects of gender on nigral gene expression and Parkinson disease. Neurobiol Dis 2007;26:606-614.
18. Nicoletti A, Arabia G, Pugliese P, et al. Hormonal replacement therapy in women with Parkinson's disease and levodopa induced dyskinesias: a cross-over clinical trial. Clin Neuropharmacol 2007;30:276-281.
19. Linazasoro G. Plasticity in Parkinson's disease: from compensatory usefulness to negative aberrant behaviours. Focus Parkinson Dis 2006;18:5-9.
20. Contin M, Martinelli P, Mochi M, et al. Dopamine transporter gene polymorphism, SPECT imaging, and levodopa response in patients with Parkinson disease. Clin Neuropharmacol 2004;27:111-115.
21. Oliveri RL, Annesi G, Zappia M, et al. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology 1999;53:1425-1430.
22. Watanabe M, Harada S, Nakamura T, et al. Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease. Neuropsychobiology 2003;48: 190-193.